Biosurgical Agents | Market Insights | US | 2021
Although it will be impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in the US will grow at a modest rate through 2029, primarily driven by growing surgical procedure volumes, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the US across a 10-year period.
